Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2026
2025
2024
2023
2022
2021

Dec 14 2022

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

Read More +

Nov 14 2022

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

Read More +

Sep 26 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Read More +

Jul 26 2022

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

Read More +

May 12 2022

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Read More +

May 9 2022

MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab

Read More +

Apr 5 2022

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Read More +

Mar 24 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

Read More +

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2026 - MoonLake Immunotherapeutics

Privacy Policy